Nyrada Inc Annual General Meeting Presentation
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more
“Looking forward, we expect Phase I studies for both the Cholesterol-Lowering and Brain Injury Programs will commence in the second… Read more
Highlights: • Cholesterol-Lowering Program advances: – New data from in vivo cholesterol study showed NYX-PCSK9i significantly increased plasma PCSK9 levels,… Read more
Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be… Read more
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
Last Friday, Nyrada released further positive results from an animal trial using a mouse model genetically modified to mimic human-like… Read more
This morning Nyrada announced the granting of a new patent by the US Patent and Trademark Office for their PCSk9i… Read more